Michael H Bloch1, Eric A Storch2. 1. Yale Child Study Center, Yale University, New Haven, CT. Electronic address: michael.bloch@yale.edu. 2. University of South Florida, Tampa, and Rogers Behavioral Health System, Tampa Bay, FL.
Abstract
OBJECTIVE: To review the assessment and treatment of treatment-refractory pediatric obsessive-compulsive disorder (OCD). METHOD: A PubMed search was conducted to identify controlled trials in pediatric OCD. In addition, practice guidelines for the treatment of adults and children were further reviewed for references in treatment-refractory OCD across the lifespan. RESULTS: Pharmacotherapy with selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy (CBT) were found to be effective treatments for pediatric OCD. Evidence suggests that CBT is also effective even in pediatric patients with refractory OCD symptoms. Antipsychotic augmentation, raising SSRI dosage, and several glutamate-modulating agents have some evidence of efficacy in adults with treatment-refractory OCD but have not been studied in pediatric populations. CONCLUSION: Several pharmacological treatment options exist for children with refractory OCD symptoms. However, little evidence-based data exist to guide treatment for our most challenging pediatric OCD patients. Further research is needed to evaluate the efficacy/side effect profile of commonly used interventions in treatment-refractory pediatric OCD.
OBJECTIVE: To review the assessment and treatment of treatment-refractory pediatric obsessive-compulsive disorder (OCD). METHOD: A PubMed search was conducted to identify controlled trials in pediatric OCD. In addition, practice guidelines for the treatment of adults and children were further reviewed for references in treatment-refractory OCD across the lifespan. RESULTS: Pharmacotherapy with selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy (CBT) were found to be effective treatments for pediatric OCD. Evidence suggests that CBT is also effective even in pediatric patients with refractory OCD symptoms. Antipsychotic augmentation, raising SSRI dosage, and several glutamate-modulating agents have some evidence of efficacy in adults with treatment-refractory OCD but have not been studied in pediatric populations. CONCLUSION: Several pharmacological treatment options exist for children with refractory OCD symptoms. However, little evidence-based data exist to guide treatment for our most challenging pediatric OCDpatients. Further research is needed to evaluate the efficacy/side effect profile of commonly used interventions in treatment-refractory pediatric OCD.
Authors: Jennifer B Freeman; Abbe M Garcia; Lisa Coyne; Chelsea Ale; Amy Przeworski; Michael Himle; Scott Compton; Henrietta L Leonard Journal: J Am Acad Child Adolesc Psychiatry Date: 2008-05 Impact factor: 8.829
Authors: Eric A Storch; Gary R Geffken; Lisa J Merlo; Giselle Mann; Danny Duke; Melissa Munson; Jennifer Adkins; Kristen M Grabill; Tanya K Murphy; Wayne K Goodman Journal: J Am Acad Child Adolesc Psychiatry Date: 2007-04 Impact factor: 8.829
Authors: Joseph F McGuire; Scott P Orr; Joey K-Y Essoe; James T McCracken; Eric A Storch; John Piacentini Journal: Expert Rev Neurother Date: 2016-06-27 Impact factor: 4.618
Authors: Katrina A Muñoz; Kristin Kostick; Laura Torgerson; Peter Zuk; Lavina Kalwani; Clarissa Sanchez; Jennifer Blumenthal-Barby; Eric A Storch; Gabriel Lázaro-Muñoz Journal: Brain Stimul Date: 2021-10-23 Impact factor: 8.955
Authors: Jafar Bakhshaie; Daniel A Geller; Sabine Wilhelm; Joseph F McGuire; Brent J Small; Sandra L Cepeda; Sophie C Schneider; Tanya K Murphy; Rachel Porth; Eric A Storch Journal: Behav Res Ther Date: 2020-07-28